Aadi Bioscience Appoints New CMO, Director
Ticker: WHWK · Form: 8-K · Filed: Aug 22, 2024 · CIK: 1422142
Sentiment: neutral
Topics: management-change, board-appointment, compensation
TL;DR
Aadi Bioscience brings in a new CMO and a new board member, expect leadership changes.
AI Summary
Aadi Bioscience, Inc. announced on August 16, 2024, the appointment of Dr. Rajul Patel as Chief Medical Officer and the election of Ms. Sarah E. Kelly to its Board of Directors. The company also disclosed compensatory arrangements for its officers, details of which are filed with this 8-K.
Why It Matters
Changes in key leadership roles like Chief Medical Officer and Board of Directors can signal strategic shifts or new directions for a biotech company's drug development and corporate governance.
Risk Assessment
Risk Level: medium — Changes in executive and board positions can indicate internal shifts that may impact the company's strategic direction and future performance.
Key Players & Entities
- Aadi Bioscience, Inc. (company) — Registrant
- Dr. Rajul Patel (person) — Appointed Chief Medical Officer
- Ms. Sarah E. Kelly (person) — Elected to Board of Directors
- August 16, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Aadi Bioscience?
Dr. Rajul Patel has been appointed as the new Chief Medical Officer of Aadi Bioscience.
Who has been elected to the Board of Directors at Aadi Bioscience?
Ms. Sarah E. Kelly has been elected to the Board of Directors at Aadi Bioscience.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 16, 2024.
What other information is disclosed regarding officers in this filing?
The filing also discloses compensatory arrangements for its officers.
What is the state of incorporation for Aadi Bioscience, Inc.?
Aadi Bioscience, Inc. is incorporated in Delaware.
Filing Stats: 777 words · 3 min read · ~3 pages · Grade level 11.7 · Accepted 2024-08-22 16:15:51
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share AADI The Nasdaq Stock Mar
- $8,000 — h in exchange for a monthly retainer of $8,000. The consulting arrangement will have a
Filing Documents
- d884557d8k.htm (8-K) — 22KB
- 0001193125-24-205370.txt ( ) — 141KB
- aadi-20240816.xsd (EX-101.SCH) — 3KB
- aadi-20240816_lab.xml (EX-101.LAB) — 18KB
- aadi-20240816_pre.xml (EX-101.PRE) — 11KB
- d884557d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 22, 2024 /s/ Scott Giacobello Scott Giacobello Chief Financial Officer